“sanofi” Archives

in
Entry Author Date Location
Stealthy X4 Pharma, Aided by Termeer, Other Ex-Genzymers, Nabs $37M+ 09/01/15 Boston
With FDA OK, Amgen’s Heart Drug Faces Rival (And Health Budgets) 08/27/15 National
Ex-Teva CEO’s Brain Disease Startup, Ovid, Bags $75M From Crossovers 08/11/15 New York
Drug Discovery in Seattle 2015: An Updated History 08/03/15 Seattle
Sanofi, Regeneron Set Sights on Immuno-Oncology With New $2B+ Pact 07/28/15 New York
Beer Out as Struggling Aegerion Shuffles Leadership Ranks 07/27/15 Boston
FDA OKs Cholesterol Fighter Praluent For More Patients Than Expected 07/24/15 New York
With $22M Shot of Venture, Sutro Spinout Aims For Better Vaccines 07/23/15 San Francisco
Scynexis Sells CRO Business to Avista, Turns Focus to Antifungal Drug 07/23/15 Raleigh Durham
East Coast Biotech Roundup: Celgene, Chiasma, Cerulean, & More 07/17/15 Boston
Texas Roundup: SailPoint, DEC, Neos, Sanofi, NASA & XPrize 07/17/15 Texas
East Coast Biotech Roundup: Biogen, Epizyme, Armored CARS, & More 07/13/15 Boston
With PCSK9’s Origins In Mind, Sanofi Has UT Join Funding Program 07/09/15 Texas
FDA Cuts Limit on Esperion Cholesterol Drug, Considers Competitors 07/07/15 Detroit Ann Arbor
How Pozen’s Tribute Pharma Deal Paves New Path for “Safer Aspirin” 06/16/15 Raleigh Durham
East Coast Biotech Roundup: XTuit, Spero, Unum, RNAi Feud & More 06/12/15 Boston
Rare Heart Disease Advocate: “I’m More Relieved Than I’ve Ever Been” 06/10/15 National
Advisors to FDA: Approve New Cholesterol Drug, But With Caveats 06/10/15 National
Take a Grain of Salt (Or Two) With New Cholesterol Drug Predictions 06/09/15 National
East Coast Biotech Roundup: Seres, Editas, PureTech, Pronutria & More 05/29/15 Boston
Retrophin Turns Asklepion Voucher Into $245M Sanofi Payday 05/27/15 New York
To Back Startups, PureTech Heads Across the Pond For $160M London IPO 05/26/15 Boston
East Coast Biotech Roundup: Bluebird, Sarepta, Synlogic & More 05/22/15 Boston
East Coast Biotech Roundup: Vertex, Moderna, Sage, ASCO & More 05/15/15 Boston
Selecta Takes Nanotech to Gene Therapy, Celiac With New Deals 05/13/15 Boston
With $46M Haul, MyoKardia Becomes Third Rock’s Latest IPO Prospect 04/30/15 San Francisco
Alnylam RNAi Drug Holds Up After Year of Treatment in Small Study 04/21/15 Boston
Hunting for an IPO? Voyager Gets $60M From “Crossover” Backers 04/13/15 Boston
Gene Therapy’s Rebirth Continues With Bristol, UniQure Cardio Deal 04/06/15 New York
Academia vs. BioPharma: Young Scientists Between A Rock and A Hard Place 04/06/15 Seattle
Page 2 of 8 « previous page · next page »